Company: PRTA
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001559053-25-000044
Chunk: 20

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
/Milestone Accounting

In December 2022, the Company received a $ 40.0

The Company is eligible to receive additional development and sales milestone payments from Novo Nordisk totaling up to $ 1.13 Novo Nordisk did not achieve any milestones under the share purchase agreement during the three and nine months ended September 30, 2025 and 2024, respectively.

The Company excluded the milestone payments in the initial transaction price because such payments are considered to be variable considerations with constraint. Such milestone payments will be recognized as revenue at a point in time when the Company can conclude it is probable that a significant revenue reversal will not occur in future periods.

Revenue Recognition

Noe three and nine months ended September 30, 2025 and 2024, respectively. The Company had noSeptember 30, 2025, and December 31, 2024, respectively.

8. Shareholders' Equity

Ordinary Shares

As of September 30, 2025, the Company had 100,000,000 0.01 53,829,982 one 16,764,284

Euro Deferred Shares

As of September 30, 2025, the Company had 10,000 22 No pari passu with the ordinary shares and are treated as a single class in all respects.

At-the-Market Offerings

In December 2021, the Company entered into an Equity Distribution Agreement (the “ December 2021 Distribution Agreement”), pursuant to which the Company could issue and sell, from time to time, the Company's ordinary shares. In connection with entering into the December 2021 Distribution Agreement, on December 23, 2021, the Company filed with the SEC a prospectus supplement relating to the offer, issuance and sale of up to $ 250.0

TheDecember2021 Prospectus was no longer effective as ofMarch 23, 2024. A s ofMarch 23, 2024, the Company had sold and issued953,589 ordinary shares pursuant to the December 2021 Distribution Agreement under theDecember 2021 Prospectus for t otal gross proceeds of approximately$ 56.3 before deducting underwriting discounts, commissions, and other offering expenses paid by the Company of$ 1.8

In February 2024, the Company amended the Equity Distribution Agreement that it entered into in December 2021 (the “ Amended Distribution Agreement”), pursuant to which the Company may issue and sell, from time